Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25735722 | 0.87 | AVPR2 (0.46) | HTTSIGMAR1MAPTRAB9AKDM4E | |
| SCHEMBL17720573 | 0.84 | HTT (0.44) | NOTUMHTTSIGMAR1MAPTRAB9A | |
| SCHEMBL16911272 | 0.84 | RAB9A (0.54) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL16202096 | 0.84 | KCNH2 (0.46) | NOTUMHTTSIGMAR1MAPTRAB9A | |
| SCHEMBL16201986 | 0.84 | KCNH2 (0.46) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL16911898 | 0.82 | RAB9A (0.50) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL27584725 | 0.80 | HTT (0.44) | HTTMAPTRAB9AKDM4EALDH1A1 | |
| SCHEMBL6623551 | 0.80 | AR (0.48) | ABL1 | |
| SCHEMBL16201987 | 0.80 | NOTUM (0.58) | NOTUMHTTMAPTRAB9AKDM4E | |
| SCHEMBL6611595 | 0.79 | AVPR2 (0.55) | HTTMAPTRAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | THE BROAD INSTITUTE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3027587-B1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE LABOR DR (ES) | 2018-07-25 | — | — | EP | disclosed |
| US-9464069-B2 | 1,2-disubstituted cyclobutyl compounds | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-11 | — | — | US | disclosed |
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2016-09-01 | — | — | US | disclosed |
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-06-30 | — | — | US | disclosed |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-05 | — | — | US | disclosed |
| WO-2010075200-A1 | 7-PHENOXYCHROMAN CARBOXYLIC ACID DERIVATIVES | ARRAY BIOPHARMA INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| EP-1358165-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-6683097-B2 | AFFINITY TO NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR SUBTYPE SELECTIVE BLOCKERS; MEDIATING PROCESSES UNDERLYING DEVELOPMENT OF CENTRAL NERVOUS SYSTEM AS WELL AS LEARNING AND MEMORY FORMATION | HOFFMANN-LA ROCHE INC. | 2004-01-27 | — | — | US | disclosed |
| US-6667335-B2 | NMDA (N-methyl-D-aspartate)-receptor subtype selective blockers | HOFFMANN-LA ROCHE INC. | 2003-12-23 | — | — | US | disclosed |
| EP-1358165-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030187268-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-6610723-B2 | Such as 3-(3,4-dimethyl-phenyl)-5-(2-methyl-imidazol-1-yl-methyl)-pyridine having affinity to N-methyl-D-aspartate-receptor subtype selective blockers; central nervous system; learning, memory, neurodegeneration | HOFFMANN-LA ROCHE INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020151715-A1 | Imidazole derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002060877-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | SNX1, DPM1, SNU13 | NOTUM 2417/4885HTT 3148/4885SIGMAR1 3897/4885 |
| US-20030191311-A1 | A 5-(imidazol-1-yl-methyl)-pyridine derivatives for treating an NMDA-receptor-mediated disease, neurodegeneration disorder caused by stroke or brain trauma, Alzheimer's disease, Parkinson's disease, Huntington's disease | GRIN1, GRIN2B, GRIN3B | NOTUM 4364/4885HTT 38/4885SIGMAR1 1952/4885 |
| US-20020151715-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | NOTUM 4107/4885HTT 2804/4885SIGMAR1 729/4885 |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | DPM1, CROCC, SNX1 | NOTUM 2527/4885HTT 2598/4885SIGMAR1 3846/4885 |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | NOTUM 2527/4885HTT 2598/4885SIGMAR1 3846/4885 |
| US-20240024490-A1 | BIFUNCTIONAL MOLECULES FOR SELECTIVE MODIFICATION OF TARGET SUBSTRATES | COASY, JMJD7, PTMS | NOTUM 590/4885HTT 3723/4885SIGMAR1 3848/4885 |
| US-20230192904-A1 | BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF | ERBB2, ACP1, TK1 | NOTUM 4125/4885HTT 4428/4885SIGMAR1 2397/4885 |
| US-20160185755-A1 | 1,2-DISUBSTITUTED CYCLOBUTYL COMPOUNDS | OPRL1, OPRK1, PTGS1 | NOTUM 3563/4885HTT 2710/4885SIGMAR1 243/4885 |
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | NOTUM 3419/4885HTT 2375/4885SIGMAR1 3639/4885 |
| US-20030187268-A1 | Imidazole derivatives | GRIN2B, GRIN1, GRIN2A | NOTUM 4107/4885HTT 2804/4885SIGMAR1 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.